Combined antitumor drug, preparation method and applications thereof

A technology of anti-tumor drugs and combined drugs, which is applied in the field of anti-tumor drugs and preparations, can solve problems such as rapid release, and achieve the effects of inhibiting proliferation, inhibiting tumor growth, and inhibiting the formation of vascular lumens

Inactive Publication Date: 2016-12-21
ZHEJIANG UNIV
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, our previous experiments showed that due to its unique chemical structure, it is difficult for SN38 to directly co-a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined antitumor drug, preparation method and applications thereof
  • Combined antitumor drug, preparation method and applications thereof
  • Combined antitumor drug, preparation method and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0042] Example 1

[0043] Take butyric acid (51.7μL, 0.57mmol), CA4 (180mg, 0.57mmol), EDC·HCl (163mg, 0.855mmol), DMAP (76.6mg, 0.627mmol), DIEA (188.9μL, 1.14mmol) and dissolve in 4ml DCM After stirring overnight at room temperature, add ethyl acetate, use 5% citric acid, saturated NaHCO 3 Wash the organic phase with saturated brine, dry the organic phase with anhydrous sodium sulfate, filter, collect the filtrate and remove the solvent under reduced pressure; the solid is separated and purified by column chromatography (ethyl acetate:n-hexane=1:3) to obtain the target The product, butyric acid-CA4 conjugate compound 2 (280 mg, yield 93%).

[0044] Product of butyric acid-CA4 1 H NMR nuclear magnetic data and mass spectrum data are as follows:

[0045] 1 H NMR(400MHz, CDCl 3 ): δ1.00-1.04(t,3H),1.73-1.78(m,2H), 2.49-2.53(t,2H), 3.71(s,6H), 3.80(s,3H), 3.83(s,3H) ), 6.45-6.45 (d, 2H, J = 1.2), 6.51 (s, 2H), 6.83-6.85 (d, 1H, J = 8.4), 7.00-7.01 (d, 1H, J = 1.6), 7.10- 7.12(q,1H)....

Example Embodiment

[0047] Example 2

[0048] Take heptanoic acid (80.8μL, 0.57mmol), CA4 (180mg, 0.57mmol), EDC·HCl (163mg, 0.855mmol), DMAP (76.6mg, 0.627mmol), DIEA (188.9μL, 1.14mmol) and dissolve in 4mL DCM After stirring overnight at room temperature, add ethyl acetate, use 5% citric acid, saturated NaHCO 3 Wash the organic phase with saturated brine, dry the organic phase with anhydrous sodium sulfate, filter, collect the filtrate and remove the solvent under reduced pressure; the solid is separated and purified by column chromatography (ethyl acetate:n-hexane=1:3) to obtain the target The product, heptanoic acid-CA4 conjugate compound 3 (260 mg, yield 85%).

[0049] Product of heptanoic acid-CA4 1 H NMR nuclear magnetic data and mass spectrum data are as follows:

[0050] 1 H NMR(400MHz, CDCl 3 ): δ0.88-0.91(t,3H),1.26-1.41(m,6H),1.70-1.74(t,2H),2.51-2.54(t,2H),3.71(s,6H),3.80(s ,3H),3.84(s,3H),6.45-6.45(d,2H,J=1.6),6.51(s,2H),6.83-6.85(d,1H,J=8.4),7.00-7.00(d, 1H, J = 1.6), 7.10-7.12 (q, 1H)...

Example Embodiment

[0052] Example 3

[0053] The synthesis method of LNA-SN38 conjugate compound 4 refers to the synthesis of SN38 prodrug 7 in the patent document "7-ethyl-10-hydroxycamptothecin prodrug and its preparation method and application", the patent application number is 201410295432. X.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a combined antitumor drug. The combined antitumor drug comprises an antiangiogenic drug, a drug used for inhibiting tumor cell proliferation, and an amphiphilic high molecular material; the antiangiogenic drug is a prodrug of Combretastatin A4, and the drug used for inhibiting tumor cell proliferation is a camptothecin antitumor drug. The invention also discloses a combined antitumor drug nanoparticle preparation, a preparation method, and applications. It is shown by cytotoxicity test that the combined antitumor drug nanoparticle preparation is capable of inhibiting proliferation of tumour cell HT-29 and human umbilical vein vascular endothelial cells (HUVEC) obviously, and dose-dependent relationship is detected; it is confirmed by scratch injury experiments and lumen formation experiments that the combined antitumor drug nanoparticle preparation is capable of inhibiting migration of HUVEC and vascularization; compared with single medication systems, the combined antitumor drug nanoparticle preparation possesses excellent tumor killing effect in vivo, clinical application value is high, and application prospect is promising.

Description

technical field [0001] The invention belongs to the field of drug synthesis, and in particular relates to an anti-angiogenesis drug and an anti-tumor cell proliferation drug combined with an anti-tumor drug, a preparation method and an application. Background technique [0002] 7-Ethyl-10-hydroxycamptothecin (SN38) is the active product of clinical antineoplastic drug irinotecan (CPT-11). SN38 takes topoisomerase as the target site, inhibits the combination of topoisomerase I-DNA complex, thereby preventing the reconnection of broken single strands, unwinding the DNA double-strand structure and exerting anti-tumor effects. SN38 exhibits higher activity in vitro, which is 100-1000 times that of CPT-11. Therefore, direct use of SN38 molecules, avoiding the way of enzymatic hydrolysis of CPT-11 to release SN38, is expected to effectively improve the anti-tumor effect of the drug. However, SN38 has poor water solubility and is insoluble in pharmaceutically acceptable solvents ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4745A61P35/00A61K47/34A61K31/222
CPCA61K31/222A61K31/4745A61K47/34A61K2300/00
Inventor 王杭祥吴佳萍陈建美谢海洋周琳郑树森
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap